Furthermore, NB-DNJ treatment restores the functionality of B and T lymphocyte attenuator (BTLA), an inhibitory receptor, similar to CTLA-4 and PD-1, in lupus CD4+ T cells [103] (Table 1). This evidence concerns the gene CD4 and systemic lupus erythematosus.